What Is Gastroenterology? A Research and Funding Guide

Gastroenterology is the branch of medicine and biomedical science that studies the digestive system: the esophagus, stomach, small and large intestine, and the organs that feed into them, namely the liver, gallbladder and bile ducts, and pancreas. It is both a clinical specialty, diagnosing and managing digestive and liver disease, often through endoscopy, and a research discipline spanning epithelial and intestinal stem cell biology, motility, immunology, microbiology, genetics, nutrition and clinical trials. (The name combines the Greek gaster, stomach, and enteron, intestine.) This guide explains what gastroenterology covers and how its subfields divide up, then adds the research-administration layer generic overviews leave out: who funds digestive disease research, how microbiome and endoscopy research work in practice, which societies and journals anchor the field, and typical training paths. It is educational, not medical advice.

What Is Gastroenterology?

The digestive system moves food along a tube, breaks it down, absorbs nutrients, and eliminates waste, while the liver and pancreas contribute bile and digestive enzymes and carry out much of the body’s metabolic processing. The discipline is organized around several interlocking questions:

• How does the gut work? Swallowing, gastric acid secretion, motility, absorption, secretion and the barrier that separates the gut lumen from the body. The lining of the intestine renews itself continuously from stem cells, which makes it a favorite system for basic biology.
• How does the gut talk to other systems? The gut contains a large immune compartment, a dense network of neurons often called the enteric nervous system, and communication with the brain. Disorders in which this signaling is disturbed are now classified together as disorders of gut-brain interaction.
• What lives in the gut? Trillions of microbes, collectively the gut microbiota, interact with the diet, the immune system and the intestinal lining. Their study is one of the fastest-moving areas of the field (see below).
• What goes wrong? Acid-related and inflammatory disease, immune-mediated conditions, infection, functional disorders, liver and pancreatic disease, and cancers of the digestive tract.
• How is disease detected and treated? Direct visualization by endoscopy, imaging, laboratory and stool tests, medication, nutrition support, and procedural therapy.

Major Subfields of Gastroenterology

• Esophageal and upper-GI disease — reflux disease, swallowing disorders, peptic ulcer disease and gastritis.
• Inflammatory bowel disease (IBD) — Crohn’s disease and ulcerative colitis, chronic immune-mediated conditions that are a major focus of translational and clinical trial work.
• Celiac disease and other immune-mediated disease — conditions in which the immune response to dietary or luminal triggers damages the gut. These overlap closely with immunology.
• Functional and motility disorders — irritable bowel syndrome, functional dyspepsia, gastroparesis and constipation or diarrhea disorders, where symptoms occur without an obvious structural cause. The Rome Foundation’s diagnostic criteria, discussed below, are the field’s reference standard.
• Hepatology — the liver and biliary tree: viral hepatitis, alcohol-related and metabolic liver disease, autoimmune and cholestatic liver disease, cirrhosis and its complications, and liver transplantation. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the current term for what was long called nonalcoholic fatty liver disease, reflecting the field’s adoption of new nomenclature in 2023.
• Pancreatic and biliary disease — acute and chronic pancreatitis and conditions of the bile ducts, often managed with advanced endoscopic procedures.
• Gastrointestinal oncology and cancer prevention — screening and surveillance for colorectal and other digestive cancers, which is one reason colonoscopy is so closely identified with the specialty.
• Pediatric gastroenterology — digestive, liver and nutritional disorders in children, including pediatric IBD and inherited liver disease.
• Therapeutic and advanced endoscopy — procedures performed through the endoscope, from removing polyps to treating bleeding and managing bile duct and pancreatic conditions.
• Gut infection and the microbiome — enteric infection, Clostridioides difficile, and the manipulation of the microbiota as a therapy.

How Gastroenterology Relates to Neighboring Disciplines

Gastroenterology sits at the junction of several research fields. It draws on microbiology for microbiome and infection work, immunology for IBD and celiac disease, nutrition science for diet, absorption and malnutrition, genomics and bioinformatics for sequencing-heavy microbiome and genetic studies, and epidemiology and biostatistics for cohort, screening and trial design. Endocrinology overlaps through obesity, diabetes and the pancreas, and nephrology shares the metabolic and fluid-balance concerns that follow from liver and bowel disease. Pharmacology matters because the liver metabolizes most drugs. For the wider map, see What Is Biology? and the overview of the branches of science; a companion explainer on the nervous system is What Is Neurology?.

Digestive Disease and Microbiome Research

The gut microbiome has become one of the most visible research themes in the field, and it shows how digestive science depends on shared infrastructure and shared methods. In the US, the NIH Common Fund supported the Human Microbiome Project (HMP) from 2007 through 2016 to build research resources for human microbiome studies. Its first phase characterized the microbial communities of healthy people; the second phase, the Integrative Human Microbiome Project, launched in 2014 and used multi-omic approaches to study microbial communities in health and in conditions that include inflammatory bowel disease.

Typical microbiome methods include:

• Culture-independent community profiling — sequencing marker genes or whole community DNA (metagenomics) from stool or mucosal samples, supported by bioinformatics pipelines and reference databases.
• Multi-omics — pairing sequencing with metabolite and protein measurements, as the Integrative Human Microbiome Project did.
• Gnotobiotic and germ-free animal models — animals raised without microbes, or with a defined set, to test cause and effect. These raise specific husbandry and oversight issues; see the guide on germ-free mice, the dictionary entries on gnotobiotic mice and specific-pathogen-free (SPF) mice, and the animal research ethics guide.
• Intestinal organoids and cell models — cultures derived from intestinal stem cells that let researchers study epithelial function, host-microbe interaction and drug response outside the body.

Microbiome-based therapy has moved from research to regulated products. On November 30, 2022, the US Food and Drug Administration approved Rebyota (Ferring), a donor-derived, rectally administered fecal microbiota product for recurrent Clostridioides difficile infection, described as the first fecal microbiota product approved by the agency. On April 26, 2023, FDA approved Vowst (Seres Therapeutics), the first fecal microbiota product for oral administration, for preventing recurrence of the same infection. Those approvals are for a specific indication; they do not establish microbiome therapy for other conditions. For administrators, microbiome studies bring particular attention to specimen consent, donor screening, sample storage and the data-sharing expectations described in the NIH Data Management and Sharing Plan guide.

Endoscopy Research

Endoscopy is both the signature procedure of gastroenterology and a research field in its own right. Fiberoptic endoscopy took shape in 1957, when Basil Hirschowitz introduced the first prototype of a fiberoptic gastroscope, and fiberoptic instruments went on to become the standard for gastrointestinal endoscopy. Modern research on endoscopy addresses instrument and imaging design, detection of precancerous lesions, endoscopic therapy, sedation and safety, and quality measurement of the procedure itself. Specific procedures commonly discussed include upper endoscopy, colonoscopy, endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound.

Endoscopy research brings operational questions that research administrators encounter directly. Reusable endoscopes must be reprocessed between patients, so protocols that involve procedures rely on facility infection-prevention practice; see the guide on endoscope reprocessing, and for the facility side the endoscopy center supply checklist. Studies that add procedure time, biopsies or research-only sampling need clear consent language and sedation planning, and device or software studies need their own regulatory review. The professional society most associated with the technique is the American Society for Gastrointestinal Endoscopy (ASGE), covered below.

How Digestive Disease Research Is Funded

In the US, the lead federal funder of digestive disease research is the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH. Within NIDDK, the Division of Digestive Diseases and Nutrition (DDN) supports research on digestive diseases, including the alimentary tract, liver and pancreas, as well as nutrition and obesity, spanning basic, translational and clinical research, research training and career development. Digestive disease program areas listed by NIDDK include gastrointestinal immunology and inflammation, microbiology and infectious diseases, neurobiology, epithelial biology, and motility and functional gastrointestinal disorders, alongside liver disease and pancreatic disease programs. NIDDK also has an intramural program that conducts laboratory and clinical research at NIH itself.

Several mechanisms matter to administrators:

• Digestive Diseases Research Core Centers. NIDDK’s Digestive Diseases Research Core Centers (P30 awards) bring together established investigators in digestive and liver disease research, with each center organized around its own theme. The centers fund shared resources (cores) and often run pilot and feasibility programs that give investigators preliminary data for larger applications.
• Investigator-initiated and cooperative awards. Standard research grants (see R01 vs. R21) sit alongside cooperative agreements such as the U01, in which NIH staff take a substantive role; see U01 vs. R01.
• Training and career awards. Early-career investigators commonly enter through mentored awards such as the K99/R00, and competitiveness varies by institute and year (see NIH paylines for FY2026).
• NIH Common Fund programs. Cross-NIH initiatives such as the Human Microbiome Project are funded outside any single institute.

Applications to NIDDK and other institutes are assessed by peer review panels; the dictionary entry on the scientific review committee explains how those groups function. Disease-focused charities and professional societies also fund fellowships, pilot projects and research awards, and non-US funders support the field through national research councils. Funding opportunities and priorities change, so always confirm current details with the funder.

Clinical Trials and Outcome Measurement

Gastroenterology trials span a wide range, from drug trials in IBD and liver disease to procedure and screening studies. Several features recur:

• Symptom-based and patient-reported outcomes. In functional disorders, outcomes are usually symptoms reported by the patient, so how the disorder is defined and how symptoms are scored matters enormously. The Rome IV criteria, released by the Rome Foundation at Digestive Disease Week in May 2016 after about five years of work by more than 120 investigators and clinicians, cover 33 adult and 17 pediatric functional gastrointestinal disorders and renamed the category as disorders of gut-brain interaction. The Rome Foundation has since announced Rome V, scheduled to ship June 1, 2026.
• Endoscopic and histologic outcomes. In diseases such as IBD, trials may combine symptom measures with what the endoscopist sees and what biopsies show. Blinded central reading of endoscopic video, to reduce variation between readers, is a recognized design feature in IBD trials (FDA’s draft ulcerative colitis guidance discusses it) that adds cost and logistics.
• Composite endpoints. Liver and pancreas trials often combine several clinical events into a single measure; see the dictionary entry on composite endpoints and the comparison of non-inferiority and superiority trial design.
• Regulatory pathways. Drug development in serious digestive and liver disease interacts with expedited pathways such as accelerated approval, which depends on the choice of surrogate endpoint.

Because many digestive conditions are chronic or recurring, administrators should expect long follow-up, biospecimen collection (stool, blood, biopsies), and careful monitoring of adverse events when budgeting these studies.

Common Research Methods and Tools

• Endoscopy with biopsy — direct visualization plus tissue for histology, culture and molecular testing.
• Physiologic testing — measuring motility, pressure and acid exposure in the esophagus, stomach and bowel.
• Laboratory and stool markers — blood tests, stool tests for inflammation and infection, and liver function tests.
• Imaging and non-invasive assessment — cross-sectional imaging and elastography-style measures of liver stiffness.
• Sequencing and multi-omics — microbiome profiling, host genetics and gene-expression studies, including single-cell methods.
• Organoids and animal models — intestinal and liver organoids and mouse models, including gnotobiotic animals.
• Cohorts, registries and screening trials — large longitudinal studies of risk factors, and studies of colorectal cancer screening and surveillance.

A Brief History

Visualizing the inside of the digestive tract has driven the field. Early gastroscopes were rigid, and the introduction of fiberoptic instruments in the late 1950s opened routine examination of the upper and lower gut. A second turning point concerned ulcers: in 2005 the Nobel Prize in Physiology or Medicine was awarded jointly to Barry Marshall and Robin Warren for the discovery of the bacterium Helicobacter pylori and its role in gastritis and peptic ulcer disease, which showed that peptic ulcer disease is an infectious condition that can be cured rather than a lifelong one. More recently, attention has shifted to the microbiome, immune-targeted therapies for IBD, and nomenclature and classification work such as the Rome criteria for functional disorders.

Societies, Meetings and Journals

The main US professional bodies, with the founding dates reported by their histories, are:

• American Gastroenterological Association (AGA), founded in 1897.
• American College of Gastroenterology (ACG), founded in 1932.
• American Society for Gastrointestinal Endoscopy (ASGE), founded in 1941 as the American Gastroscopic Club to give physicians practicing gastroscopy a forum on methods and instruments.
• American Association for the Study of Liver Diseases (AASLD), founded in 1950 for the field of hepatology.

Four organizations, the AGA, AASLD, ASGE and the Society for Surgery of the Alimentary Tract (SSAT), jointly sponsor Digestive Disease Week (DDW), the field’s largest annual meeting. Outside the US, bodies such as the British Society of Gastroenterology and United European Gastroenterology fill similar roles, and the Rome Foundation maintains the diagnostic criteria for functional disorders.

Leading journals include Gastroenterology and Clinical Gastroenterology and Hepatology (AGA), the American Journal of Gastroenterology (ACG), Gastrointestinal Endoscopy (ASGE), Hepatology (AASLD), Gut, and the Journal of Hepatology. Society guidelines published in these journals often shape trial eligibility criteria and standards of care, so reviewers of a protocol will usually expect it to cite the relevant one.

Career and Training Pathways

The clinical path runs through medical school, an internal medicine residency (or pediatrics, for pediatric gastroenterology), and a gastroenterology fellowship. In the US, the American Board of Internal Medicine certifies gastroenterologists on the basis of prior internal medicine certification, an unrestricted license, completion of accredited fellowship training that includes documented endoscopy skills, and a passing score on the Gastroenterology Certification Examination. Confirm the current months-of-training requirements with ABIM. Many academic gastroenterologists add research years, and there is a separate board pathway for transplant hepatology.

The research path runs through graduate study in cell and molecular biology, immunology, microbiology, genetics, nutrition or epidemiology, typically a PhD followed by postdoctoral training. Physician-scientists often combine fellowship with research training supported by mentored K awards, and NIDDK’s training programs and the Digestive Diseases Research Core Centers’ pilot programs are common early-career entry points.

Gastroenterology and Research Administration

For research offices, digestive disease studies share a recognizable administrative profile: human biospecimens and stool collection that need consent and storage plans; procedures and sedation that need clinical-site coordination; animal and gnotobiotic facilities that need oversight; sequencing data that fall under data-sharing expectations; industry-sponsored IBD and liver trials with long follow-up; and multi-site consortia and core centers with shared resources. Understanding the vocabulary above, the funders and the typical outcomes makes it easier to review budgets, compliance plans and data management plans for these projects.

Frequently Asked Questions

What is gastroenterology in simple terms?

Gastroenterology is the study of the digestive system and its diseases. It covers how the esophagus, stomach, intestines, liver, gallbladder and pancreas work, why they become diseased, and how conditions such as reflux, inflammatory bowel disease, liver disease and digestive cancers are diagnosed, studied and managed.

What is the difference between gastroenterology and hepatology?

Hepatology is the branch concerned with the liver, gallbladder and bile ducts, and it is closely tied to gastroenterology. Many physicians are trained in both; transplant hepatology has its own board pathway in the US.

What do gastroenterologists study or treat?

They study and treat conditions of the digestive tract and liver, including reflux, ulcers, inflammatory bowel disease, celiac disease, functional bowel disorders, pancreatic and bile duct disease, and digestive cancers, and many perform endoscopic procedures such as colonoscopy.

Who funds digestive disease research?

In the US the lead federal funder is NIH’s NIDDK, particularly through its Division of Digestive Diseases and Nutrition and the Digestive Diseases Research Core Centers. Cross-NIH programs such as the Human Microbiome Project, charities and professional societies add to this.

Is microbiome research the same as gastroenterology?

No. Microbiome research spans many body sites and fields. It is closely tied to gastroenterology because the gut hosts the largest microbial community in the body, and the first FDA-approved microbiome-based therapies treat a gut infection, recurrent C. difficile.

How long does it take to become a gastroenterologist?

In the US, after medical school and an internal medicine residency, ABIM requires completion of accredited gastroenterology fellowship training; confirm the current length with ABIM. Research years are common for academic careers.

Which professional societies cover gastroenterology?

In the US, the AGA, ACG, ASGE and AASLD are the principal ones, and together with SSAT the AGA, AASLD and ASGE sponsor Digestive Disease Week. Internationally, bodies such as the British Society of Gastroenterology and United European Gastroenterology are examples.

Related Guides

This guide is part of a series on scientific disciplines from a research-administration perspective. See the overview of the branches of science, the companion guides What Is Nephrology?, What Is Endocrinology? and What Is Neurology?, and What Is Microbiology?.